Bristol R&D Update: Apixaban Filing Delayed, Ipilimumab Approval Expected

Contrary to expectations, Bristol-Myers Squibb will not file early for a narrow indication of the novel anticoagulant apixaban.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Pink Sheet